Get the Stockscreener App
2.00
4.76%
-0.10
After Hours:
2.03
0.03
+1.50%
In 8 Bio Inc stock is traded at $2.00, with a volume of 70,650.
It is down -4.76% in the last 24 hours and down -15.61% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
See More
Previous Close:
$2.10
Open:
$2.11
24h Volume:
70,650
Relative Volume:
0.61
Market Cap:
$9.08M
Revenue:
-
Net Income/Loss:
$-31.88M
P/E Ratio:
-2.6667
EPS:
-0.75
Net Cash Flow:
$-25.20M
1W Performance:
-7.41%
1M Performance:
-15.61%
6M Performance:
-70.42%
1Y Performance:
-78.94%
1-Day Range:
$1.99
$2.165
1-Week Range:
$1.91
$2.20
52-Week Range:
$1.91
$16.70
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.00 | 9.53M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.21 | 101.15B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.14 | 61.07B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.59 | 59.35B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.83 | 46.29B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.27 | 35.69B | 3.81B | -644.79M | -669.77M | -6.24 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
Novartis to acquire Tourmaline Bio for $1.4 billion - Reuters
Tourmaline Bio to Be Acquired by Novartis; $47.95M Termination Fee, Option Cashouts - Stock Titan
Remedium Bio Announces Strategic Collaboration With Lilly to Develop Gene Therapies for Obesity and Type 2 Diabetes - BioSpace
KALA BIO Soars 10.65% on Bullish Analyst Coverage - AInvest
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Does Gossamer Bio Inc. align with a passive investing strategyJuly 2025 Analyst Calls & Weekly High Conviction Ideas - خودرو بانک
Layoff Tracker: AC Immune To Cut 30% of Workforce - BioSpace
Rare Eye Disease Biotech KALA BIO to Present Latest Developments at H.C. Wainwright Conference - Stock Titan
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
Canopy Growth, Nvidia And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director - GlobeNewswire
Adicet Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference - The Globe and Mail
Gamma Delta T Cell Therapy Pioneer Adicet Bio to Showcase Latest Developments at Global Investment Conference - Stock Titan
First-in-Class TSLP Antibody Results: Upstream Bio's Verekitug Phase 2 Trial in Nasal Polyps Coming - Stock Titan
Signal strength of KALA BIO Inc. stock in tech scannersJuly 2025 Recap & Weekly Market Pulse Alerts - Newser
Is Palisade Bio Inc. trending in predictive chart modelsMarket Sentiment Review & Weekly Hot Stock Watchlists - Newser
Historical volatility pattern of GRI Bio Inc. visualizedDay Trade & Fast Momentum Entry Tips - Newser
Will a bounce in Instil Bio Inc. offer an exit2025 Biggest Moves & AI Powered Buy and Sell Recommendations - Newser
TELA Bio Inc. stock momentum explainedJuly 2025 Patterns & Stock Market Timing Techniques - Newser
Understanding Instil Bio Inc.’s price movementMarket Growth Review & Safe Swing Trade Setups - Newser
Regression analysis insights on GRI Bio Inc. performanceJuly 2025 Review & Fast Gaining Stock Reports - Newser
How to forecast Passage Bio Inc. trends using time series2025 Market WrapUp & Free Real-Time Market Sentiment Alerts - Newser
84,000 Shares at $0.72: Adicet Bio's Latest Inducement Grants Under Nasdaq Rule 5635(c)(4) - Stock Titan
Smart tools for monitoring KALA BIO Inc.’s price actionAnalyst Upgrade & Proven Capital Preservation Tips - Newser
PAH Drug Developer Gossamer Bio Set for Key Presentations at Cantor, Wells Fargo, HC Wainwright Events - Stock Titan
Is Nuvation Bio Inc. stock poised for growthJuly 2025 Breakouts & AI Optimized Trade Strategies - Newser
Trend analysis for Adicet Bio Inc. this weekBull Run & Stock Timing and Entry Methods - Newser
What candlestick patterns are forming on bluebird bio Inc.Stop Loss & Free AI Powered Buy and Sell Recommendations - Newser
What’s next for INmune Bio Inc. stock priceWeekly Trade Review & Entry Point Confirmation Signals - Newser
Genetic Medicines Pioneer Passage Bio to Showcase Neurodegenerative Disease Pipeline at Global Conference - Stock Titan
Visualizing Third Harmonic Bio Inc. stock with heatmaps2025 Momentum Check & Free Expert Verified Stock Movement Alerts - Newser
Global Oncology Company Nuvation Bio Announces Triple Conference Schedule for September 2025 - Stock Titan
Is now a turning point for Adicet Bio Inc.Weekly Risk Summary & Daily Oversold Stock Bounce Ideas - Newser
Clinical-Stage Biotech Belite Bio Secures Speaking Slots at Three Premier Healthcare Conferences - Stock Titan
Live market analysis of Third Harmonic Bio Inc.2025 Market Trends & Scalable Portfolio Growth Methods - Newser
H.C. Wainwright Reiterates a Buy Rating on Nuvation Bio (NUVB) - MSN
Combining price and volume data for Nuvation Bio Inc.Dip Buying & Safe Swing Trade Setups - Newser
GRI Bio Inc. stock prediction for this weekQuarterly Trade Report & Daily Stock Trend Reports - Newser
Is Palisade Bio Inc. stock ready for a breakoutBear Alert & Low Drawdown Momentum Trade Ideas - Newser
Stop Loss: Is Upstream Bio Inc. forming a double bottomJuly 2025 Chart Watch & Risk Controlled Stock Pick Alerts - theviewers.co.kr
Mustang Bio Inc. stock trend forecastJuly 2025 Summary & Verified Momentum Watchlists - Newser
Volume spikes in Palisade Bio Inc. stock – what they meanWeekly Market Outlook & Precise Swing Trade Alerts - Newser
Using economic indicators to assess Cabaletta Bio Inc. potentialWeekly Market Outlook & Low Volatility Stock Suggestions - Newser
Is Third Harmonic Bio Inc. building a consolidation baseJuly 2025 Catalysts & Long-Term Capital Growth Strategies - Newser
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):